ParkinsonCanadaV1, Main, Exploration, bibRecord, 002F18

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Identifieur interne : 002F18 ( Main/Exploration ); précédent : 002F17; suivant : 002F19

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Auteurs : A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]

Source :

Advances in neurology [ 0091-3952 ] ; 2003.

RBID : Pascal:03-0411829

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Traitement, Lévodopa, Chimiothérapie, Homme, Antiparkinsonien.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Animals, Antiparkinson agent, Brain (drug effects), Brain (metabolism), Brain (physiopathology), Chemotherapy, Disease Models, Animal, Dopamine (metabolism), Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), Dyskinesia, Drug-Induced (prevention & control), Human, Humans, Levodopa, Levodopa (adverse effects), Neural Pathways (drug effects), Neural Pathways (metabolism), Neural Pathways (physiopathology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Receptors, Dopamine (drug effects), Receptors, Dopamine (metabolism), Treatment.
MESH :
- chemical , adverse effects : Levodopa.
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Dopamine, Receptors, Dopamine.
- drug effects : Brain, Neural Pathways.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- metabolism : Brain, Neural Pathways, Parkinson Disease.
- physiopathology : Brain, Dyskinesia, Drug-Induced, Neural Pathways, Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Animals, Disease Models, Animal, Humans.

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>The Institut Universitaire de Gériatrie de Montreal</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>The Institut Universitaire de Gériatrie de Montreal</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0411829</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0411829 INIST</idno>
<idno type="RBID">Pascal:03-0411829</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A58</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000265</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000937</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000937</idno>
<idno type="wicri:doubleKey">0091-3952:2003:Hadj Tahar A:new:insights:in</idno>
<idno type="wicri:Area/Main/Merge">003323</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12442663</idno>
<idno type="wicri:Area/PubMed/Corpus">001464</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001464</idno>
<idno type="wicri:Area/PubMed/Curation">001464</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001464</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001464</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001464</idno>
<idno type="wicri:Area/Ncbi/Merge">000260</idno>
<idno type="wicri:Area/Ncbi/Curation">000260</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000260</idno>
<idno type="wicri:doubleKey">0091-3952:2003:Hadj Tahar A:new:insights:in</idno>
<idno type="wicri:Area/Main/Merge">003151</idno>
<idno type="wicri:Area/Main/Curation">002F18</idno>
<idno type="wicri:Area/Main/Exploration">002F18</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>The Institut Universitaire de Gériatrie de Montreal</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>The Institut Universitaire de Gériatrie de Montreal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>The Institut Universitaire de Gériatrie de Montreal</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Unité de Recherche en Oncologie and Endocrinologie Moléculaire, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson agent</term>
<term>Brain (drug effects)</term>
<term>Brain (metabolism)</term>
<term>Brain (physiopathology)</term>
<term>Chemotherapy</term>
<term>Disease Models, Animal</term>
<term>Dopamine (metabolism)</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Neural Pathways (drug effects)</term>
<term>Neural Pathways (metabolism)</term>
<term>Neural Pathways (physiopathology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (metabolism)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Neural Pathways</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Traitement</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Antiparkinsonien</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
</noRegion>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A." last="Hadj Tahar">A. Hadj Tahar</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F18 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F18 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:03-0411829
   |texte=   New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.